RxDoctor Payments Data

Eliana Lopez, MD

Infectious Disease · Bronx, NYNPI 1740578269

Payments from drug & device makers

$7,286in general payments, 2019–2025

Across 250 payments — averaging $29.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$4K
  • Gilead$2K
  • Janssen Products, LP$553
  • AbbVie$316
  • Johnson & Johnson$257
  • Merck$115
  • plus $126 from 3 others

What the payments were for

  • Food & beverage$7,10297%
  • Education$1843%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,286 in reported general payments places this provider in the 80th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$7,876
Medicare patients
24
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala83$321,191
DovatoDolutegravir Sodium/Lamivudine63$179,879
CabenuvaCabotegravir/Rilpivirine11$71,372
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf14$61,129
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$55,607
JulucaDolutegravir/Rilpivirine14$52,344
OdefseyEmtricitab/Rilpiviri/Tenof Ala14$48,042
TivicayDolutegravir Sodium11$27,642
Atovaquone19$4,606
Entecavir21$1,252
Albuterol Sulfate HfaAlbuterol Sulfate20$890
Azelastine Hcl32$468
Atorvastatin Calcium92$461
ValacyclovirValacyclovir Hcl17$455
Omeprazole47$329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$1,672$376,79896 claims
Viiv Healthcare CompanyDovato, Cabenuva, Juluca, Tivicay$4,247$331,23799 claims
Janssen Products, LPSymtuza$553$61,12914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 799 infectious disease providers in New York.

Other infectious disease in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →